NASDAQ:RTRX - Retrophin Stock Price, Price Target & More

$26.85 +0.06 (+0.22 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$26.79
Today's Range$26.09 - $27.04
52-Week Range$15.55 - $28.25
Volume263,529 shs
Average Volume315,310 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.05

About Retrophin (NASDAQ:RTRX)

Retrophin logoRetrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Debt-to-Equity Ratio0.15%
Current Ratio3.80%
Quick Ratio3.74%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$154.94 million
Price / Sales6.91
Cash FlowN/A
Price / CashN/A
Book Value$7.46 per share
Price / Book3.60

Profitability

EPS (Most Recent Fiscal Year)($1.50)
Net Income$-59,730,000.00
Net Margins-38.55%
Return on Equity-13.98%
Return on Assets-8.11%

Miscellaneous

Employees173
Outstanding Shares39,860,000

How to Become a New Pot Stock Millionaire

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin (NASDAQ:RTRX) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.20. The biopharmaceutical company had revenue of $42.18 million for the quarter, compared to the consensus estimate of $42.20 million. Retrophin had a negative net margin of 38.55% and a negative return on equity of 13.98%. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Retrophin.

What price target have analysts set for RTRX?

1 equities research analysts have issued 12 month price targets for Retrophin's stock. Their predictions range from $43.00 to $43.00. On average, they expect Retrophin's share price to reach $43.00 in the next twelve months. View Analyst Ratings for Retrophin.

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Gary A. Lyons, Independent Chairman of the Board (Age 66)
  • Stephen J. Aselage, President, Chief Executive Officer, Director (Age 65)
  • Laura M. Clague CPA, Chief Financial Officer, Senior Vice President (Age 58)
  • Neil McFarlane, Chief Operating Officer (Age 44)
  • Elizabeth E. Reed, Senior Vice President, General Counsel and Corporate Secretary (Age 46)
  • William E. Rote Ph.D., Senior Vice President and Head of Research and Development (Age 54)
  • Casey Logan, Vice President - Corporate Development
  • Roy D. Baynes M.D. Ph.D., Independent Director (Age 62)
  • Timothy P. Coughlin CPA, Independent Director (Age 50)
  • John W. Kozarich, Independent Director (Age 67)

Has Retrophin been receiving favorable news coverage?

Media headlines about RTRX stock have been trending positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Retrophin earned a news impact score of 0.29 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.18 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $26.85.

How big of a company is Retrophin?

Retrophin has a market capitalization of $1.07 billion and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (RTRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Retrophin (NASDAQ:RTRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Retrophin in the last 12 months. Their average twelve-month price target is $43.00, suggesting that the stock has a possible upside of 60.15%. The high price target for RTRX is $43.00 and the low price target for RTRX is $43.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.00$44.00$44.00$36.00
Price Target Upside: 60.15% upside77.85% upside77.85% upside45.51% upside

Retrophin (NASDAQ:RTRX) Consensus Price Target History

Price Target History for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ:RTRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$44.00 -> $43.00HighView Rating Details
4/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/AView Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Retrophin (NASDAQ:RTRX) Earnings History and Estimates Chart

Earnings by Quarter for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ:RTRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.84)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.20)($0.20)($0.20)
Q2 20181($0.31)($0.31)($0.31)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.14)($0.14)($0.14)

Retrophin (NASDAQ RTRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.45)N/AView Earnings Details
2/27/2018Q4 2017($0.19)($0.39)$42.20 million$42.18 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.25)($0.46)$40.51 million$40.34 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.24)($0.34)$37.36 million$38.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.22)$0.01$36.20 million$33.62 millionViewListenView Earnings Details
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.08)$32.80 million$33.31 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.23 million$17.37 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)$8.35 millionViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
11/18/2013Q3 2013($0.33)ViewN/AView Earnings Details
9/16/2013Q2 2013($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Retrophin (NASDAQ:RTRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Retrophin (NASDAQ RTRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.67%
Insider Trading History for Retrophin (NASDAQ:RTRX)
Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ RTRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018William E RoteSVPSell1,034$21.50$22,231.0011,156View SEC Filing  
1/5/2018Elizabeth E ReedSVPSell942$24.04$22,645.689,058View SEC Filing  
8/16/2017Neil F McfarlaneCOOSell1,378$22.50$31,005.0013,622View SEC Filing  
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00248,756View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00158,334View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50167,084View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.0052,000View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.0047,000View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50175,834View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50184,584View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.0050,000View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00193,334View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Retrophin (NASDAQ RTRX) News Headlines

Source:
DateHeadline
Retrophin (RTRX) Set to Announce Quarterly Earnings on TuesdayRetrophin (RTRX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 10:56 AM
Retrophin (RTRX) Expected to Announce Quarterly Sales of $39.65 MillionRetrophin (RTRX) Expected to Announce Quarterly Sales of $39.65 Million
www.americanbankingnews.com - April 21 at 3:50 AM
Shkreli arrives at low-security prison in New JerseyShkreli arrives at low-security prison in New Jersey
finance.yahoo.com - April 19 at 5:08 PM
-$0.27 EPS Expected for Retrophin (RTRX) This Quarter-$0.27 EPS Expected for Retrophin (RTRX) This Quarter
www.americanbankingnews.com - April 19 at 1:18 PM
Retrophin (RTRX) Upgraded by ValuEngine to HoldRetrophin (RTRX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 17 at 10:55 PM
Retrophin to Report First Quarter 2018 Financial ResultsRetrophin to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 17 at 5:22 PM
Retrophin (RTRX) Downgraded by ValuEngineRetrophin (RTRX) Downgraded by ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM
Retrophin (RTRX) Lifted to "Buy" at BidaskClubRetrophin (RTRX) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 12 at 10:20 AM
Retrophin (RTRX) Upgraded to "Hold" by ValuEngineRetrophin (RTRX) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 10 at 12:35 AM
Leerink Swann Equities Analysts Raise Earnings Estimates for Retrophin Inc (RTRX)Leerink Swann Equities Analysts Raise Earnings Estimates for Retrophin Inc (RTRX)
www.americanbankingnews.com - April 6 at 7:58 AM
Retrophin (RTRX) Commences Pivotal Phase 3 Clinical Trial of SparsentanRetrophin (RTRX) Commences Pivotal Phase 3 Clinical Trial of Sparsentan
www.streetinsider.com - April 5 at 10:57 AM
BMO Capital Markets Cuts Retrophin (RTRX) Price Target to $43.00BMO Capital Markets Cuts Retrophin (RTRX) Price Target to $43.00
www.americanbankingnews.com - April 4 at 11:00 AM
Retrophin Inc (RTRX) Expected to Announce Quarterly Sales of $38.05 MillionRetrophin Inc (RTRX) Expected to Announce Quarterly Sales of $38.05 Million
www.americanbankingnews.com - April 4 at 3:41 AM
Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental GlomerulosclerosisRetrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
finance.yahoo.com - April 3 at 9:02 AM
Retrophin (RTRX) Rating Lowered to Sell at ValuEngineRetrophin (RTRX) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 12:30 AM
Zacks: Brokerages Expect Retrophin Inc (RTRX) to Announce -$0.31 EPSZacks: Brokerages Expect Retrophin Inc (RTRX) to Announce -$0.31 EPS
www.americanbankingnews.com - April 2 at 1:15 PM
Retrophin (RTRX) Upgraded at BidaskClubRetrophin (RTRX) Upgraded at BidaskClub
www.americanbankingnews.com - March 29 at 3:36 PM
Pharma bro Martin Shkreli appeals fraud conviction as judge mulls restitution awardPharma bro Martin Shkreli appeals fraud conviction as judge mulls restitution award
finance.yahoo.com - March 27 at 4:49 PM
Retrophin Inc (RTRX) Receives Average Rating of "Hold" from BrokeragesRetrophin Inc (RTRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 26 at 3:07 AM
Shkreli bragged exam would would show 150 IQ and no overt psychological issues. — He was wrongShkreli bragged exam would would show 150 IQ and 'no overt psychological issues.' — He was wrong
finance.yahoo.com - March 24 at 9:19 AM
BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With RetrophinBRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin
www.reuters.com - March 22 at 5:05 PM
Retrophin (RTRX) Downgraded to "Hold" at BidaskClubRetrophin (RTRX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 22 at 11:35 AM
Aurinia Pharmaceuticals: Creating Value While Executing Its Business StrategyAurinia Pharmaceuticals: Creating Value While Executing Its Business Strategy
seekingalpha.com - March 22 at 9:07 AM
Aurnia Pharmaceuticals: Creating Value While Executing Its Business StrategyAurnia Pharmaceuticals: Creating Value While Executing Its Business Strategy
seekingalpha.com - March 21 at 9:47 AM
Retrophin Inc (RTRX) Expected to Post Quarterly Sales of $38.05 MillionRetrophin Inc (RTRX) Expected to Post Quarterly Sales of $38.05 Million
www.americanbankingnews.com - March 18 at 5:00 AM
Zacks: Analysts Anticipate Retrophin Inc (RTRX) to Announce -$0.31 EPSZacks: Analysts Anticipate Retrophin Inc (RTRX) to Announce -$0.31 EPS
www.americanbankingnews.com - March 16 at 11:46 AM
Shkreli asks judge to recommend a high-security federal prison in PennsylvaniaShkreli asks judge to recommend a high-security federal prison in Pennsylvania
www.bizjournals.com - March 14 at 6:25 PM
Pharma Bro Martin Shkreli Gets 7 Years In Prison For Securities Fraud'Pharma Bro' Martin Shkreli Gets 7 Years In Prison For Securities Fraud
finance.yahoo.com - March 9 at 6:08 PM
Martin Shkreli Sentenced to Seven Years in PrisonMartin Shkreli Sentenced to Seven Years in Prison
finance.yahoo.com - March 9 at 6:08 PM
Pharma Bro Shkreli sentenced to 7 years for defrauding investors'Pharma Bro' Shkreli sentenced to 7 years for defrauding investors
finance.yahoo.com - March 9 at 6:08 PM
Martin Shkreli’s journey from pharma executive to inmate No. 87850-053Martin Shkreli’s journey from pharma executive to inmate No. 87850-053
www.latimes.com - March 9 at 3:07 PM
Martin Shkreli’s Journey From Pharma Exec to Inmate #87850-053Martin Shkreli’s Journey From Pharma Exec to Inmate #87850-053
finance.yahoo.com - March 8 at 6:00 PM
Bogle Investment Management L P DE Purchases 4,112 Shares of Retrophin Inc (RTRX)Bogle Investment Management L P DE Purchases 4,112 Shares of Retrophin Inc (RTRX)
www.americanbankingnews.com - March 6 at 5:08 AM
Retrophin Announces Appointment of Casey Logan as Vice President of Corporate DevelopmentRetrophin Announces Appointment of Casey Logan as Vice President of Corporate Development
finance.yahoo.com - March 5 at 5:27 PM
Emory University Grows Position in Retrophin Inc (RTRX)Emory University Grows Position in Retrophin Inc (RTRX)
www.americanbankingnews.com - March 4 at 2:59 PM
Retrophin (RTRX) Rating Increased to Buy at BidaskClubRetrophin (RTRX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 3 at 5:42 PM
Lombard Odier Asset Management USA Corp Lowers Stake in Retrophin Inc (RTRX)Lombard Odier Asset Management USA Corp Lowers Stake in Retrophin Inc (RTRX)
www.americanbankingnews.com - March 2 at 6:16 PM
'Pharma bro' Martin Shkreli tells judge: 'I was a fool''Pharma bro' Martin Shkreli tells judge: 'I was a fool'
finance.yahoo.com - March 2 at 8:50 AM
Zacks: Brokerages Anticipate Retrophin Inc (RTRX) Will Post Quarterly Sales of $37.55 MillionZacks: Brokerages Anticipate Retrophin Inc (RTRX) Will Post Quarterly Sales of $37.55 Million
www.americanbankingnews.com - March 1 at 12:10 PM
Retrophin Inc (RTRX) Receives Consensus Recommendation of "Hold" from AnalystsRetrophin Inc (RTRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 1 at 3:34 AM
Pharma bro Shkreli seeks 12 to 18 month sentence, below guidelines'Pharma bro' Shkreli seeks 12 to 18 month sentence, below guidelines
finance.yahoo.com - February 28 at 5:31 PM
Pharma bro Martin Shkreli tells judge: I was a fool'Pharma bro' Martin Shkreli tells judge: 'I was a fool'
finance.yahoo.com - February 28 at 5:31 PM
Retrophin to Present at the Barclays Global Healthcare ConferenceRetrophin to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - February 28 at 5:31 PM
Retrophin Q4 Earnings PreviewRetrophin Q4 Earnings Preview
finance.yahoo.com - February 27 at 5:28 PM
Retrophin Reports Fourth Quarter and Full Year 2017 Financial ResultsRetrophin Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 5:28 PM
Big 'loss' for Martin Shkreli: Judge's ruling means 'pharma bro' could get decade or more in prisonBig 'loss' for Martin Shkreli: Judge's ruling means 'pharma bro' could get decade or more in prison
finance.yahoo.com - February 26 at 5:21 PM
Pharma bro Shkreli to be held responsible for $10.4 million in losses: U.S. judge'Pharma bro' Shkreli to be held responsible for $10.4 million in losses: U.S. judge
finance.yahoo.com - February 26 at 5:21 PM
Retrophin Inc (RTRX) Position Raised by Spark Investment Management LLCRetrophin Inc (RTRX) Position Raised by Spark Investment Management LLC
www.americanbankingnews.com - February 26 at 3:02 PM
Martin Shkreli sports a jailhouse beard as judge weighs big questions on investors' lossesMartin Shkreli sports a jailhouse beard as judge weighs big questions on investors' losses
finance.yahoo.com - February 23 at 5:25 PM
Shkreli loses bid to toss stock manipulation convictionShkreli loses bid to toss stock manipulation conviction
finance.yahoo.com - February 23 at 5:25 PM

SEC Filings

Retrophin (NASDAQ:RTRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Retrophin (NASDAQ:RTRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Retrophin (NASDAQ RTRX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.